The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding

Its most notable role is recommending whether a substance belongs on the Section 503A bulks list, the roster of ingredients state-licensed pharmacies may use to compound patient-specific prescriptions outside the standard drug-approval process. The PCAC meeting held on July 23–24 to consider seven bulk peptide substances drew unusual scrutiny for two reasons. Eight of its 14 members are recent appointees under US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., several with reported ties to peptide clinics or businesses. And peptides such as BPC-157 and TB-500 have surged in popularity across the wellness, athletic recovery, and telehealth markets, giving the panel’s recommendations outsized stakes for a large and rapidly growing base of patients, providers, and compounders.

Over two days, that panel cast its votes, delivering six recommendations in favor of expanded access, and just one against. The panel broke with the FDA’s own scientific staff on vote after vote, sending a clear signal to compounders, telehealth platforms, and the broader wellness industry that the regulatory ground is shifting.

This is the closest thing the peptide industry has had to a watershed moment. Still, a favorable vote is not a finish line, and a considerable regulatory road remains.

PCAC Convenes to Review Seven Bulk Peptide Substances for 503A Compounding

As we previously discussed, this PCAC meeting had been looming as the next concrete milestone in the FDA’s slow-moving reclassification of these substances. The lineup included BPC-157, KPV, TB-500, and MOTS-c (considered on day one) and Emideltide (also known as DSIP, or delta sleep-inducing peptide), Semax, and Epitalon (considered on day two).

Any interested party, typically a manufacturer, compounder, trade association, or individual clinician, may nominate a bulk drug substance for inclusion on the 503A bulks list, and the FDA’s practice has been to bring nominated substances before the PCAC for evaluation before deciding whether to add them through rulemaking. A nominator’s role is thus to trigger and support the substance’s candidacy, not to make the final call, which rests with the FDA. In a twist that caught many observers off guard, the original nominators for all seven substances withdrew their nominations shortly before the meeting without public explanation. The FDA nonetheless elected to evaluate each substance on its own initiative, citing significant public interest in the outcomes. As we previously wrote, this decision aligned with the current Administration’s broader health agenda, which has placed expanded peptide access among its priorities.

Notably, the FDA’s own multidisciplinary scientific review team recommended against inclusion for all seven substances. The staff cited recurring threshold concerns: unresolved questions of substance identity and characterization, limited efficacy data, immunogenicity and impurity risks (particularly given that most nominated uses involve injection), and the availability of approved alternative therapies for several of the proposed indications.

Day One: Committee Recommends All Four Substances Reviewed

On July 23, despite the staff’s across-the-board negative recommendations, the PCAC voted to recommend all four day one substances for inclusion on the Category 1 list.

• BPC-157 (both free base and acetate forms): Passed 8-6 with one abstention.

• KPV (both free base and acetate forms): Passed 8-6 with one abstention.

• TB-500 (both free base and acetate forms): Passed 8-6 with one abstention.

• MOTS-c: Passed by a narrower margin of 7-5 with two abstentions.

Public comment during day one revealed a sharp divide. On one side, industry representatives and clinicians argued for a regulated 503A pathway with meaningful guardrails, including FDA-registered supplier greenlists, mandatory adverse event reporting, and patient disclosure requirements making clear that products are compounded (not FDA-approved). On the other side, public health advocates urged the panel to reject all nominations, warning that injectable routes of administration pose heightened safety risks, that listing could be misread by patients as an FDA stamp of approval, and that the precedent would undermine incentives for manufacturers to pursue formal drug development through the investigational new drug pathway.

Day Two: Committee Recommends Two Substances, Rejects Emideltide

On July 24, the panel turned to the remaining three substances, and for the first time across the two-day proceeding, said no to one of them.

• Emideltide (DSIP): Evaluated for insomnia, opioid withdrawal, and narcotic dependence. Voted down 6-7 with one abstention. This was the sole rejection of the entire two-day meeting.

• Semax: Evaluated for cerebral ischemia, migraine, and trigeminal neuralgia. Passed 8-5.

• Epitalon: Evaluated for insomnia. Passed 7-5 with one abstention. This outcome is particularly striking given that FDA staff observed Epitalon has no registered clinical trials and a notably thin evidence base supporting its proposed use

The overall pattern is unmistakable: the committee’s votes ran contrary to FDA staff’s briefing recommendations against inclusion for all seven substances. That pattern is consistent with the broader political environment, in which Secretary Kennedy has publicly advocated for expanded patient access to peptides as part of the Administration’s health freedom platform.

Key Caveats Before Acting on the PCAC Recommendations

Before clients begin retooling their operations around these outcomes, a healthy dose of regulatory realism is in order. Here are the key considerations.

• Advisory only. PCAC recommendations are non-binding. The FDA retains full discretion to accept, reject, or modify the panel’s recommendations.

• Rulemaking lies ahead. Even with favorable recommendations in hand, the FDA must still complete formal (and often lengthy) notice-and-comment rulemaking before any substance is officially added to the Category 1 bulks list. No substance was “approved” at the meeting itself.

• The interim question. A critical open question is whether the FDA will place the six favorably-voted substances on the interim Category 1 list pending completion of rulemaking, and whether the agency will exercise enforcement discretion for compounders who begin (or continue) using these substances in the interim period.

• Enforcement is not on pause. Regardless of the bulks list trajectory, the FDA’s active enforcement focus on peptide marketing claims remains very much alive. As we previously wrote, the agency has issued a stream of warning letters targeting compounders and telehealth platforms over advertising that creates misleading net impressions under Section 502(a) of the Federal Food, Drug, and Cosmetic Act, and a favorable PCAC vote does not insulate promotional materials from scrutiny.

• Monitor the docket. Clients should actively track FDA announcements for forthcoming proposed rules, comment periods, and any interim guidance the FDA may issue.

Next Steps: Rulemaking, Enforcement Discretion, and Industry Preparation

The PCAC’s two-day session marks an inflection point for peptide compounding regulation, but it is the opening act rather than the finale. The real action will unfold in the months ahead as the FDA decides whether to place the six favorably-voted substances into interim Category 1 with accompanying enforcement discretion, or to proceed directly to formal rulemaking without any interim relief. Compounders, telehealth platforms, and life sciences companies should use this window to refine their regulatory positioning and prepare to engage the notice-and-comment process.